MX2010004389A - Formulaciones de vancomicina liposomales. - Google Patents

Formulaciones de vancomicina liposomales.

Info

Publication number
MX2010004389A
MX2010004389A MX2010004389A MX2010004389A MX2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A
Authority
MX
Mexico
Prior art keywords
liposomal vancomycin
vancomycin formulations
liposomal
present disclosure
compositions
Prior art date
Application number
MX2010004389A
Other languages
English (en)
Inventor
Xingong Li
Walter R Perkins
Original Assignee
Transave Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave Inc filed Critical Transave Inc
Publication of MX2010004389A publication Critical patent/MX2010004389A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere en parte a composiciones de vancomicina liposomales que tienen bajas relaciones de lípidos a fármacos y alta concentración de vancomicina. La presente descripción también se refiere en parte a métodos para formar dichas composiciones.
MX2010004389A 2007-10-23 2008-10-23 Formulaciones de vancomicina liposomales. MX2010004389A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98199007P 2007-10-23 2007-10-23
US10372508P 2008-10-08 2008-10-08
PCT/US2008/080954 WO2009055568A2 (en) 2007-10-23 2008-10-23 Liposomal vancomycin formulations

Publications (1)

Publication Number Publication Date
MX2010004389A true MX2010004389A (es) 2010-05-20

Family

ID=40563728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004389A MX2010004389A (es) 2007-10-23 2008-10-23 Formulaciones de vancomicina liposomales.

Country Status (8)

Country Link
US (2) US20090104257A1 (es)
EP (1) EP2214645A4 (es)
JP (3) JP5855829B2 (es)
CN (2) CN101917972A (es)
AU (2) AU2008316841B2 (es)
CA (1) CA2703179C (es)
MX (1) MX2010004389A (es)
WO (2) WO2009055568A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1962805T3 (pl) 2005-12-08 2017-01-31 Insmed Incorporated Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
RU2608390C2 (ru) * 2010-05-20 2017-01-18 Семпра Фармасьютикалз, Инк. Способы получения макролидов и кетолидов, и промежуточных соединений для их получения
CN107261110A (zh) * 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
WO2012020790A1 (ja) * 2010-08-11 2012-02-16 学校法人慶應義塾 感染症治療薬
MX354575B (es) * 2010-10-22 2018-03-12 Dr Reddys Laboratories Inc Uso de depósito de fosfolípidos viscosos estables en almacenamiento para tratar heridas..
CA2834353A1 (en) * 2011-04-26 2012-11-01 Cedars-Sinai Medical Center Liposomal vancomycin for the treatment of mrsa infections
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
EA201490047A1 (ru) * 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
CA2891487A1 (en) * 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
PL3142643T3 (pl) 2014-05-15 2019-12-31 Insmed Incorporated Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
WO2017083403A1 (en) * 2015-11-10 2017-05-18 Children's Research Institute, Children's National Medical Center Echinomycin formulation, method of making and method of use thereof
JP6949849B2 (ja) * 2016-01-15 2021-10-13 サイドース ファーマ エルエルシー バンコマイシンの製剤
US20200368312A1 (en) * 2017-05-22 2020-11-26 Insmed Incorporated Glycopeptide derivative compounds and uses thereof
US20200368313A1 (en) * 2017-12-29 2020-11-26 Wayne State University Drug delivery systems for treatment of infections
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
US20220296515A1 (en) * 2019-05-28 2022-09-22 Nevakar Injectables Inc. Vancomycin Liposome Compositions and Methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
JPH06345663A (ja) * 1993-06-08 1994-12-20 Sumitomo Pharmaceut Co Ltd バンコマイシン含有リポソーム製剤
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
MXPA05004580A (es) * 2002-10-29 2005-07-26 Transave Inc Liberacion sostenida de anti - infecciosos.
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
US20070105757A1 (en) * 2005-10-31 2007-05-10 May Thomas B Vancomycin formulations having reduced amount of histamine

Also Published As

Publication number Publication date
CN101917972A (zh) 2010-12-15
JP5855829B2 (ja) 2016-02-09
CA2703179A1 (en) 2009-04-30
AU2008316841B2 (en) 2014-04-17
AU2014202745B2 (en) 2016-11-24
WO2009055571A2 (en) 2009-04-30
JP2016130262A (ja) 2016-07-21
WO2009055568A3 (en) 2009-09-24
JP2011500836A (ja) 2011-01-06
US20090105126A1 (en) 2009-04-23
US20090104257A1 (en) 2009-04-23
EP2214645A4 (en) 2013-09-25
CA2703179C (en) 2016-06-07
EP2214645A2 (en) 2010-08-11
WO2009055568A2 (en) 2009-04-30
AU2008316841A1 (en) 2009-04-30
AU2014202745A1 (en) 2014-06-12
JP2014098032A (ja) 2014-05-29
CN103860469A (zh) 2014-06-18

Similar Documents

Publication Publication Date Title
MX2010004389A (es) Formulaciones de vancomicina liposomales.
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
WO2009099719A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
PH12015501192A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
GEP20156253B (en) Lyophilized therapeutic peptibody formulations
WO2009149418A3 (en) Compositions for the in vivo delivery of rnai agents
MY161991A (en) Proteasome inhibitors
MX2009003548A (es) Formulaciones que contienen lipidos.
MX2012012837A (es) Composiciones farmaceuticas y metodos para su elaboracion.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
AU2008313418A8 (en) Composition for regulating lipid metabolism
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EP2320740A4 (en) PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS THEREOF
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
MY161390A (en) Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
WO2008016730A3 (en) Compositions and methods for reducing cellular fat
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
PH12014500714A1 (en) Stable sns-595 compositions and methods of preparation
MXPA05008902A (es) Soluciones de drogas en mentol.

Legal Events

Date Code Title Description
FG Grant or registration